Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial
ContributorsBetticher, Daniel C; Hsu Schmitz, Shu-Fang; Totsch, Martin; Hansen, Eva; Joss, Christine; von Briel, Christian; Schmid, Ralph A; Pless, Miklos; Habicht, James; Roth, Arnaud; Spiliopoulos, Anastase; Stahel, Rolf; Weder, Walter; Stupp, Roger; Egli, Fritz; Furrer, Markus; Honegger, Hanspeter; Wernli, Martin; Cerny, Thomas; Ris, Hans-Beat
Published inJournal of clinical oncology, vol. 21, no. 9, p. 1752-1759
Publication date2003
Abstract
Keywords
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Carcinoma, Non-Small-Cell Lung/drug therapy/pathology/surgery
- Cisplatin/administration & dosage
- Female
- Humans
- Infusions, Intravenous
- Lung Neoplasms/drug therapy/pathology/surgery
- Lymphatic Metastasis/pathology
- Male
- Middle Aged
- Neoadjuvant Therapy
- Neoplasm Staging
- Paclitaxel/administration & dosage/analogs & derivatives
- Prognosis
- Survival
- Taxoids
- Treatment Outcome
Research groups
Citation (ISO format)
BETTICHER, Daniel C et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. In: Journal of clinical oncology, 2003, vol. 21, n° 9, p. 1752–1759. doi: 10.1200/JCO.2003.11.040
Main files (1)
Article (Published version)
Identifiers
- PID : unige:43975
- DOI : 10.1200/JCO.2003.11.040
- PMID : 12721251
Journal ISSN0732-183X
